{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["androgen-insensitive", "androgen-sensitive", "apoptosis", "curcumin", "in vitro", "in vivo", "polyphenol", "proliferation", "prostate cancer", "survival"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "33182828", "DateCompleted": {"Year": "2021", "Month": "09", "Day": "07"}, "DateRevised": {"Year": "2021", "Month": "09", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "11", "Day": "10"}], "Language": ["eng"], "ELocationID": ["1536", "10.3390/biom10111536"], "Journal": {"ISSN": "2218-273X", "JournalIssue": {"Volume": "10", "Issue": "11", "PubDate": {"Year": "2020", "Month": "Nov", "Day": "10"}}, "Title": "Biomolecules", "ISOAbbreviation": "Biomolecules"}, "ArticleTitle": "Curcumin against Prostate Cancer: Current Evidence.", "Abstract": {"AbstractText": ["Cancer is a condition characterized by remarkably enhanced rates of cell proliferation paired with evasion of cell death. These deregulated cellular processes take place following genetic mutations leading to the activation of oncogenes, the loss of tumor suppressor genes, and the disruption of key signaling pathways that control and promote homeostasis. Plant extracts and plant-derived compounds have historically been utilized as medicinal remedies in different cultures due to their anti-inflammatory, antioxidant, and antimicrobial properties. Many chemotherapeutic agents used in the treatment of cancer are derived from plants, and the scientific interest in discovering plant-derived chemicals with anticancer potential continues today. Curcumin, a turmeric-derived polyphenol, has been reported to possess antiproliferative and proapoptotic properties. In the present review, we summarize all the in vitro and in vivo studies examining the effects of curcumin in prostate cancer."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada."}], "LastName": "Termini", "ForeName": "Deborah", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada."}, {"Identifier": [], "Affiliation": "Centre for Bone and Muscle Health, Brock University, St. Catharines, ON L2S 3A1, Canada."}], "LastName": "Den Hartogh", "ForeName": "Danja J", "Initials": "DJ"}, {"Identifier": ["0000-0001-6946-3108"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada."}], "LastName": "Jaglanian", "ForeName": "Alina", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada."}, {"Identifier": [], "Affiliation": "Centre for Bone and Muscle Health, Brock University, St. Catharines, ON L2S 3A1, Canada."}], "LastName": "Tsiani", "ForeName": "Evangelia", "Initials": "E"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Biomolecules", "NlmUniqueID": "101596414", "ISSNLinking": "2218-273X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "IT942ZTH98", "NameOfSubstance": "Curcumin"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Curcumin"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Expression Regulation, Neoplastic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug therapy", "genetics", "metabolism", "physiopathology"], "DescriptorName": "Prostatic Neoplasms"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Lodish H., Berk A., Zipursky S.L., Matsudaira P., Baltimore D., Darnell J. Molecular Cell Biology. 4th ed. W. H. Freeman and Company; New York, NY, USA: 2000. Proto-Oncogenes and Tumor-Suppressor Genes."}, {"Citation": "Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Sarkar S., Horn G., Moulton K., Oza A., Byler S., Kokolus S., Longacre M. Cancer Development, Progression, and Therapy: An Epigenetic Overview. Int. J. Mol. Sci. 2013;14:21087\u201321113. doi: 10.3390/ijms141021087.", "ArticleIdList": ["10.3390/ijms141021087", "PMC3821660", "24152442"]}, {"Citation": "Mattiuzzi C., Lippi G. Current Cancer Epidemiology. J. Epidemiol. Glob. Health. 2019;9:217\u2013222. doi: 10.2991/jegh.k.191008.001.", "ArticleIdList": ["10.2991/jegh.k.191008.001", "PMC7310786", "31854162"]}, {"Citation": "Leslie S.W., Soon-Sutton T.L., Sajjad H., Siref L.E. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2020. Prostate Cancer."}, {"Citation": "Rawla P. Epidemiology of Prostate Cancer. World J. Oncol. 2019;10:63\u201389. doi: 10.14740/wjon1191.", "ArticleIdList": ["10.14740/wjon1191", "PMC6497009", "31068988"]}, {"Citation": "Davey R.A., Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin. Biochem. Rev. 2016;37:3\u201315.", "ArticleIdList": ["PMC4810760", "27057074"]}, {"Citation": "Yang Q., Fung K.-M., Day W.V., Kropp B.P., Lin H.-K. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int. 2005;5:8\u201318. doi: 10.1186/1475-2867-5-8.", "ArticleIdList": ["10.1186/1475-2867-5-8", "PMC1087496", "15813967"]}, {"Citation": "Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin. Oncol. 1999;26:407\u2013421.", "ArticleIdList": ["10482183"]}, {"Citation": "Ramsay A.K., Leung H.Y. Signalling pathways in prostate carcinogenesis: Potentials for molecular-targeted therapy. Clin. Sci. 2009;117:209\u2013228. doi: 10.1042/CS20080391.", "ArticleIdList": ["10.1042/CS20080391", "19663810"]}, {"Citation": "Sharifi N., Gulley J.L., Dahut W.L. Androgen Deprivation Therapy for Prostate Cancer. JAMA. 2005;294:238\u2013244. doi: 10.1001/jama.294.2.238.", "ArticleIdList": ["10.1001/jama.294.2.238", "16014598"]}, {"Citation": "Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer. 2001;1:34\u201345. doi: 10.1038/35094009.", "ArticleIdList": ["10.1038/35094009", "11900250"]}, {"Citation": "Lawrentschuk N., Trottier G., Kuk C., Zlotta A.R. Role of surgery in high-risk localized prostate cancer. Curr. Oncol. 2010;17:25\u201332. doi: 10.3747/co.v17i0.705.", "ArticleIdList": ["10.3747/co.v17i0.705", "PMC2935705", "20882128"]}, {"Citation": "Bill-Axelson A., Holmberg L., Ruutu M., Garmo H., Stark J.R., Busch C., Nordling S., H\u00e4ggman M., Andersson S.-O., Bratell S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 2011;364:1708\u20131717. doi: 10.1056/NEJMoa1011967.", "ArticleIdList": ["10.1056/NEJMoa1011967", "21542742"]}, {"Citation": "Hayden A.J., Catton C., Pickles T. Radiation therapy in prostate cancer: A risk-adapted strategy. Curr. Oncol. 2010;17(Suppl. S2):18\u201324. doi: 10.3747/co.v17i0.704.", "ArticleIdList": ["10.3747/co.v17i0.704", "PMC2935704", "20882127"]}, {"Citation": "Morton G.C., Hoskin P.J. Brachytherapy: Current status and future strategies\u2014Can high dose rate replace low dose rate and external beam radiotherapy? Clin. Oncol. R Coll. Radiol. 2013;25:474\u2013482. doi: 10.1016/j.clon.2013.04.009.", "ArticleIdList": ["10.1016/j.clon.2013.04.009", "23727431"]}, {"Citation": "Huggins C., Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 2002;168:9\u201312. doi: 10.1016/S0022-5347(05)64820-3.", "ArticleIdList": ["10.1016/S0022-5347(05)64820-3", "12050481"]}, {"Citation": "Perlmutter M.A., Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 2007;9(Suppl. S1):3\u20138.", "ArticleIdList": ["PMC1831539", "17387371"]}, {"Citation": "Isbarn H., Boccon-Gibod L., Carroll P.R., Montorsi F., Schulman C., Smith M.R., Sternberg C.N., Studer U.E. Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks. Eur. Urol. 2009;55:62\u201375. doi: 10.1016/j.eururo.2008.10.008.", "ArticleIdList": ["10.1016/j.eururo.2008.10.008", "PMC3090670", "18945543"]}, {"Citation": "Picard J.C., Golshayan A.-R., Marshall D.T., Opfermann K.J., Keane T.E. The multi-disciplinary management of high-risk prostate cancer. Urol. Oncol. 2012;30:3\u201315. doi: 10.1016/j.urolonc.2009.09.002.", "ArticleIdList": ["10.1016/j.urolonc.2009.09.002", "19945310"]}, {"Citation": "Tannock I.F., de Witt R., Berry W.R., Horty J., Pluzanska A., Chi K.N., Oudard S.C., Th\u00e9odore C., James N.D., Turesson I., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004;351:1502\u20131512. doi: 10.1056/NEJMoa040720.", "ArticleIdList": ["10.1056/NEJMoa040720", "15470213"]}, {"Citation": "Paller C.J., Antonarakis E.S. Management of Biochemically Recurrent Prostate Cancer After Local Therapy: Evolving Standards of Care and New Directions. Clin. Adv. Hematol. Oncol. 2013;11:14\u201323.", "ArticleIdList": ["PMC3624708", "23416859"]}, {"Citation": "Karantanos T., Corn P.G., Thompson T.C. Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501\u20135511. doi: 10.1038/onc.2013.206.", "ArticleIdList": ["10.1038/onc.2013.206", "PMC3908870", "23752182"]}, {"Citation": "Baskar R., Lee K.A., Yeo R., Yeoh K.-W. Cancer and Radiation Therapy: Current Advances and Future Directions. Int J. Med. Sci. 2012;9:193\u2013199. doi: 10.7150/ijms.3635.", "ArticleIdList": ["10.7150/ijms.3635", "PMC3298009", "22408567"]}, {"Citation": "Nepple K.G., Stephenson A.J., Kallogjeri D., Michalski J., Grubb R.L., Strope S.A., Haslag-Minoff J., Piccirillo J.F., Ciezki J.P., Klein E.A., et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur. Urol. 2013;64:372\u2013378. doi: 10.1016/j.eururo.2013.03.005.", "ArticleIdList": ["10.1016/j.eururo.2013.03.005", "PMC3930076", "23506834"]}, {"Citation": "Nader R., El Amm J., Aragon-Ching J.B. Role of chemotherapy in prostate cancer. Asian J. Androl. 2018;20:221\u2013229. doi: 10.4103/aja.aja_40_17.", "ArticleIdList": ["10.4103/aja.aja_40_17", "PMC5952475", "29063869"]}, {"Citation": "Chen F., Zhao X. Prostate Cancer: Current Treatment and Prevention Strategies. Iran. Red Crescent Med. J. 2013;15:279\u2013284. doi: 10.5812/ircmj.6499.", "ArticleIdList": ["10.5812/ircmj.6499", "PMC3785898", "24082997"]}, {"Citation": "Litwin M.S., Tan H.-J. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017;317:2532\u20132542. doi: 10.1001/jama.2017.7248.", "ArticleIdList": ["10.1001/jama.2017.7248", "28655021"]}, {"Citation": "Gillet J.-P., Varma S., Gottesman M.M. The Clinical Relevance of Cancer Cell Lines. J. Natl. Cancer Inst. 2013;105:452\u2013458. doi: 10.1093/jnci/djt007.", "ArticleIdList": ["10.1093/jnci/djt007", "PMC3691946", "23434901"]}, {"Citation": "Mirabelli P., Coppola L., Salvatore M. Cancer Cell Lines Are Useful Model Systems for Medical Research. Cancers. 2019;11:1098. doi: 10.3390/cancers11081098.", "ArticleIdList": ["10.3390/cancers11081098", "PMC6721418", "31374935"]}, {"Citation": "Niu N., Wang L. In vitro human cell line models to predict clinical response to anticancer drugs. Pharmacogenomics. 2015;16:273\u2013285. doi: 10.2217/pgs.14.170.", "ArticleIdList": ["10.2217/pgs.14.170", "PMC4358765", "25712190"]}, {"Citation": "Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3) Invest. Urol. 1979;17:16\u201323.", "ArticleIdList": ["447482"]}, {"Citation": "Seim I., Jeffery P.L., Thomas P.B., Nelson C.C., Chopin L.K. Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines. G3 (Bethesda) 2017;7:1731\u20131741. doi: 10.1534/g3.117.039909.", "ArticleIdList": ["10.1534/g3.117.039909", "PMC5473753", "28413162"]}, {"Citation": "Tararova N.D., Narizhneva N., Krivokrisenko V., Gudkov A.V., Gurova K.V. Prostate Cancer Cells Tolerate a Narrow Range of Androgen Receptor Expression and Activity. Prostate. 2007;67:1801\u20131815. doi: 10.1002/pros.20662.", "ArticleIdList": ["10.1002/pros.20662", "PMC2914504", "17935158"]}, {"Citation": "Tai S., Sun Y., Squires J.M., Zhang H., Oh W.K., Liang C.-Z., Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011;71:1668\u20131679. doi: 10.1002/pros.21383.", "ArticleIdList": ["10.1002/pros.21383", "PMC3426349", "21432867"]}, {"Citation": "Gaupel A.-C., Wang W.-L.W., Mordan-McCombs S., Yu Lee E.C., Tenniswood M. Xenograft, Transgenic, and Knockout Models of Prostate Cancer. In: Conn P.M., editor. Animal Models for the Study of Human Disease. Academic Press; Boston, MA, USA: 2013. pp. 973\u2013995. (Chapter 39)."}, {"Citation": "Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F. Isolation of a human prostate carcinoma cell line (DU 145) Int. J. Cancer. 1978;21:274\u2013281. doi: 10.1002/ijc.2910210305.", "ArticleIdList": ["10.1002/ijc.2910210305", "631930"]}, {"Citation": "Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 1993;23:123\u2013134. doi: 10.1002/pros.2990230206.", "ArticleIdList": ["10.1002/pros.2990230206", "8104329"]}, {"Citation": "Pretlow T.G., Wolman S.R., Micale M.A., Pelley R.J., Kursh E.D., Resnick M.I., Bodner D.R., Jacobberger J.W., Delmoro C.M., Giaconia J.M., et al. Xenografts of Primary Human Prostatic Carcinoma. J. Natl. Cancer. Inst. 1993;85:394\u2013398. doi: 10.1093/jnci/85.5.394.", "ArticleIdList": ["10.1093/jnci/85.5.394", "8433392"]}, {"Citation": "Sramkoski R.M., Pretlow T.G., Giaconia J.M., Pretlow T.P., Schwartz S., Sy M.S., Marengo S.R., Rhim J.S., Zhang D., Jacobberger J.W. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell. Dev. Biol. Anim. 1999;35:403\u2013409. doi: 10.1007/s11626-999-0115-4.", "ArticleIdList": ["10.1007/s11626-999-0115-4", "10462204"]}, {"Citation": "Hartel A., Didier A., Ulbrich S.E., Wierer M., Meyer H.H.D. Characterisation of steroid receptor expression in the human prostate carcinoma cell line 22RV1 and quantification of androgen effects on mRNA regulation of prostate-specific genes. J. Steroid Biochem. Mol. Biol. 2004;92:187\u2013197. doi: 10.1016/j.jsbmb.2004.07.004.", "ArticleIdList": ["10.1016/j.jsbmb.2004.07.004", "15555912"]}, {"Citation": "Wang X., Tryndyak V., Apostolov E.O., Yin X., Shah S.V., Pogribny I.P., Basnakian A.G. Sensitivity of human prostate cancer cells to chemotherapeutic drugs depends on EndoG expression regulated by promoter methylation. Cancer Lett. 2008;270:132\u2013143. doi: 10.1016/j.canlet.2008.04.053.", "ArticleIdList": ["10.1016/j.canlet.2008.04.053", "PMC5091799", "18565644"]}, {"Citation": "Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43:1809\u20131818.", "ArticleIdList": ["6831420"]}, {"Citation": "Spans L., Atak Z.K., Van Nieuwerburgh F., Deforce D., Lerut E., Aerts S., Claessens F. Variations in the exome of the LNCaP prostate cancer cell line. Prostate. 2012;72:1317\u20131327. doi: 10.1002/pros.22480.", "ArticleIdList": ["10.1002/pros.22480", "22213130"]}, {"Citation": "Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 1990;173:534\u2013540. doi: 10.1016/S0006-291X(05)80067-1.", "ArticleIdList": ["10.1016/S0006-291X(05)80067-1", "2260966"]}, {"Citation": "Thalmann G.N., Sikes R.A., Wu T.T., Degeorges A., Chang S.M., Ozen M., Pathak S., Chung L.W. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate. 2000;44:91\u2013103. doi: 10.1002/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L.", "ArticleIdList": ["10.1002/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L", "10881018"]}, {"Citation": "Jiang X., Chen S., Asara J.M., Balk S.P. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J. Biol. Chem. 2010;285:14980\u201314989. doi: 10.1074/jbc.M109.085696.", "ArticleIdList": ["10.1074/jbc.M109.085696", "PMC2865293", "20231295"]}, {"Citation": "Dorai T., Dutcher J.P., Dempster D.W., Wiernik P.H. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate. 2004;60:1\u201317. doi: 10.1002/pros.10359.", "ArticleIdList": ["10.1002/pros.10359", "15129424"]}, {"Citation": "Vlachojannis J., Magora F., Chrubasik S. Willow species and aspirin: Different mechanism of actions. Phytother. Res. 2011;25:1102\u20131104. doi: 10.1002/ptr.3386.", "ArticleIdList": ["10.1002/ptr.3386", "21226125"]}, {"Citation": "Ziegler J., Facchini P.J., Geissler R., Schmidt J., Ammer C., Kramell R., Voigtl\u00e4nder S., Gesell A., Pienkny S., Brandt W. Evolution of morphine biosynthesis in opium poppy. Phytochemistry. 2009;70:1696\u20131707. doi: 10.1016/j.phytochem.2009.07.006.", "ArticleIdList": ["10.1016/j.phytochem.2009.07.006", "19665152"]}, {"Citation": "Kampan N.C., Madondo M.T., McNally O.M., Quinn M., Plebanski M. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed. Res. Int. 2015 doi: 10.1155/2015/413076.", "ArticleIdList": ["10.1155/2015/413076", "PMC4475536", "26137480"]}, {"Citation": "Demain A.L., Vaishnav P. Natural products for cancer chemotherapy. Microb. Biotechnol. 2011;4:687\u2013699. doi: 10.1111/j.1751-7915.2010.00221.x.", "ArticleIdList": ["10.1111/j.1751-7915.2010.00221.x", "PMC3815406", "21375717"]}, {"Citation": "Hewlings S.J., Kalman D.S. Curcumin: A Review of Its\u2019 Effects on Human Health. Foods. 2017;6:92. doi: 10.3390/foods6100092.", "ArticleIdList": ["10.3390/foods6100092", "PMC5664031", "29065496"]}, {"Citation": "Dorai T., Gehani N., Katz A. Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis. 2000;3:84\u201393. doi: 10.1038/sj.pcan.4500399.", "ArticleIdList": ["10.1038/sj.pcan.4500399", "12497104"]}, {"Citation": "Mukhopadhyay A., Bueso-Ramos C., Chatterjee D., Pantazis P., Aggarwal B.B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 2001;20:7597\u20137609. doi: 10.1038/sj.onc.1204997.", "ArticleIdList": ["10.1038/sj.onc.1204997", "11753638"]}, {"Citation": "Nakamura K., Yasunaga Y., Segawa T., Ko D., Moul J.W., Srivastava S., Rhim J.S. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int. J. Oncol. 2002;21:825\u2013830. doi: 10.3892/ijo.21.4.825.", "ArticleIdList": ["10.3892/ijo.21.4.825", "12239622"]}, {"Citation": "Mukhopadhyay A., Banerjee S., Stafford L.J., Xia C., Liu M., Aggarwal B.B. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene. 2002;21:8852\u20138861. doi: 10.1038/sj.onc.1206048.", "ArticleIdList": ["10.1038/sj.onc.1206048", "12483537"]}, {"Citation": "Deeb D., Xu Y.X., Jiang H., Gao X., Janakiraman N., Chapman R.A., Gautam S.C. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol. Cancer Ther. 2003;2:95\u2013103.", "ArticleIdList": ["12533677"]}, {"Citation": "Chaudhary L.R., Hruska K.A. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J. Cell. Biochem. 2003;89:1\u20135. doi: 10.1002/jcb.10495.", "ArticleIdList": ["10.1002/jcb.10495", "12682902"]}, {"Citation": "Deeb D., Jiang H., Gao X., Hafner M.S., Wong H., Divine G., Chapman R.A., Dulchavsky S.A., Gautam S.C. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol. Cancer Ther. 2004;3:803\u2013812.", "ArticleIdList": ["15252141"]}, {"Citation": "Shankar S., Srivastava R.K. Involvement of Bcl-2 family members, phosphatidylinositol 3\u2019-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int. J. Oncol. 2007;30:905\u2013918. doi: 10.3892/ijo.30.4.905.", "ArticleIdList": ["10.3892/ijo.30.4.905", "17332930"]}, {"Citation": "Shankar S., Chen Q., Sarva K., Siddiqui I., Srivastava R.K. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: Molecular mechanisms of apoptosis, migration and angiogenesis. J. Mol. Signal. 2007;10:10\u201314. doi: 10.1186/1750-2187-2-10.", "ArticleIdList": ["10.1186/1750-2187-2-10", "PMC2082014", "17916240"]}, {"Citation": "Srivastava R.K., Chen Q., Siddiqui I., Sarva K., Shankar S. Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1) Cell Cycle. 2007;6:2953\u20132961. doi: 10.4161/cc.6.23.4951.", "ArticleIdList": ["10.4161/cc.6.23.4951", "18156803"]}, {"Citation": "Choi H.Y., Lim J.E., Hong J.H. Curcumin interrupts the interaction between the androgen receptor and Wnt/\u03b2-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis. 2010;13:343\u2013349. doi: 10.1038/pcan.2010.26.", "ArticleIdList": ["10.1038/pcan.2010.26", "20680030"]}, {"Citation": "Yu S., Shen G., Khor T.O., Kim J.-H., Kong A.-N.T. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol. Cancer Ther. 2008;7:2609\u20132620. doi: 10.1158/1535-7163.MCT-07-2400.", "ArticleIdList": ["10.1158/1535-7163.MCT-07-2400", "PMC2596943", "18790744"]}, {"Citation": "Hilchie A.L., Furlong S.J., Sutton K., Richardson A., Robichaud M.R.J., Giacomantonio C.A., Ridgway N.D., Hoskin D.W. Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria. Nutr. Cancer. 2010;62:379\u2013389. doi: 10.1080/01635580903441238.", "ArticleIdList": ["10.1080/01635580903441238", "20358476"]}, {"Citation": "Rivera M., Ramos Y., Rodr\u00edguez-Valent\u00edn M., L\u00f3pez-Acevedo S., Cubano L.A., Zou J., Zhang Q., Wang G., Boukli N.M. Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells. PLoS ONE. 2017;12:1\u201325. doi: 10.1371/journal.pone.0179587.", "ArticleIdList": ["10.1371/journal.pone.0179587", "PMC5476315", "28628644"]}, {"Citation": "Zhu M., Zheng Z., Huang J., Ma X., Huang C., Wu R., Li X., Liang Z., Deng F., Wu J., et al. Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells. J. Cell. Biochem. 2019;120:15616\u201315624. doi: 10.1002/jcb.28828.", "ArticleIdList": ["10.1002/jcb.28828", "31042325"]}, {"Citation": "Zhang H.-N., Yu C.-X., Zhang P.-J., Chen W.-W., Jiang A.-L., Kong F., Deng J.-T., Zhang J.-Y., Young C.Y. Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharm. Sin. 2007;28:423\u2013430. doi: 10.1111/j.1745-7254.2007.00501.x.", "ArticleIdList": ["10.1111/j.1745-7254.2007.00501.x", "17303007"]}, {"Citation": "Li M., Zhang Z., Hill D.L., Wang H., Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 2007;67:1988\u20131996. doi: 10.1158/0008-5472.CAN-06-3066.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-3066", "17332326"]}, {"Citation": "Deeb D., Jiang H., Gao X., Al-Holou S., Danyluk A.L., Dulchavsky S.A., Gautam S.C. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. J. Pharm. Exp. Ther. 2007;321:616\u2013625. doi: 10.1124/jpet.106.117721.", "ArticleIdList": ["10.1124/jpet.106.117721", "17289836"]}, {"Citation": "Nonn L., Duong D., Peehl D.M. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis. 2007;28:1188\u20131196. doi: 10.1093/carcin/bgl241.", "ArticleIdList": ["10.1093/carcin/bgl241", "17151092"]}, {"Citation": "Thangapazham R.L., Shaheduzzaman S., Kim K.-H., Passi N., Tadese A., Vahey M., Dobi A., Srivastava S., Maheshwari R.K. Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome. Cancer Biol. Ther. 2008;7:1427\u20131435. doi: 10.4161/cbt.7.9.6469.", "ArticleIdList": ["10.4161/cbt.7.9.6469", "18719366"]}, {"Citation": "Tsui K.-H., Feng T.-H., Lin C.-M., Chang P.-L., Juang H.-H. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J. Androl. 2008;29:661\u2013668. doi: 10.2164/jandrol.108.004911.", "ArticleIdList": ["10.2164/jandrol.108.004911", "18676361"]}, {"Citation": "Piantino C.B., Salvadori F.A., Ayres P.P., Kato R.B., Srougi V., Leite K.R., Srougi M. An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines. Int. Braz. J. Urol. 2009;35:354\u2013360. doi: 10.1590/S1677-55382009000300012.", "ArticleIdList": ["10.1590/S1677-55382009000300012", "19538771"]}, {"Citation": "Slusarz A., Shenouda N.S., Sakla M.S., Drenkhahn S.K., Narula A.S., MacDonald R.S., Besch-Williford C.L., Lubahn D.B. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010;70:3382\u20133390. doi: 10.1158/0008-5472.CAN-09-3012.", "ArticleIdList": ["10.1158/0008-5472.CAN-09-3012", "20395211"]}, {"Citation": "Teiten M.-H., Gaascht F., Cronauer M., Henry E., Dicato M., Diederich M. Anti-proliferative potential of curcumin in androgen-dependent prostate cancer cells occurs through modulation of the Wingless signaling pathway. Int. J. Oncol. 2011;38:603\u2013611. doi: 10.3892/ijo.2011.905.", "ArticleIdList": ["10.3892/ijo.2011.905", "21240460"]}, {"Citation": "Chung L.-C., Tsui K.-H., Feng T.-H., Lee S.-L., Chang P.-L., Juang H.-H. Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells. Mol. Nutr Food Res. 2011;55:1666\u20131676. doi: 10.1002/mnfr.201100328.", "ArticleIdList": ["10.1002/mnfr.201100328", "21936051"]}, {"Citation": "Khor T.O., Huang Y., Wu T.-Y., Shu L., Lee J., Kong A.-N.T. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem. Pharmacol. 2011;82:1073\u20131078. doi: 10.1016/j.bcp.2011.07.065.", "ArticleIdList": ["10.1016/j.bcp.2011.07.065", "21787756"]}, {"Citation": "Shu L., Khor T.O., Lee J.-H., Boyanapalli S.S.S., Huang Y., Wu T.-Y., Saw C.L.-L., Cheung K.-L., Kong A.-N.T. Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPS J. 2011;13:606\u2013614. doi: 10.1208/s12248-011-9300-y.", "ArticleIdList": ["10.1208/s12248-011-9300-y", "PMC3231852", "21938566"]}, {"Citation": "Teiten M.-H., Gaigneaux A., Chateauvieux S., Billing A.M., Planchon S., Fack F., Renaut J., Mack F., Muller C.P., Dicato M., et al. Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines. OMICS. 2012;16:289\u2013300. doi: 10.1089/omi.2011.0136.", "ArticleIdList": ["10.1089/omi.2011.0136", "22475723"]}, {"Citation": "Sundram V., Chauhan S.C., Ebeling M., Jaggi M. Curcumin attenuates \u03b2-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS ONE. 2012;7:1\u201313. doi: 10.1371/journal.pone.0035368.", "ArticleIdList": ["10.1371/journal.pone.0035368", "PMC3327669", "22523587"]}, {"Citation": "Cheng T.-S., Chen W.-C., Lin Y.-Y., Tsai C.-H., Liao C.-I., Shyu H.-Y., Ko C.-J., Tzeng S.-F., Huang C.-Y., Yang P.-C., et al. Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis. Cancer Prev Res. (Phila) 2013;6:495\u2013505. doi: 10.1158/1940-6207.CAPR-12-0293-T.", "ArticleIdList": ["10.1158/1940-6207.CAPR-12-0293-T", "23466486"]}, {"Citation": "Rodriguez-Garcia A., Hevia D., Mayo J.C., Gonzalez-Menendez P., Lu J., Holmgren A., Sainz R.M. Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells. Redox Biol. 2017;12:634\u2013647. doi: 10.1016/j.redox.2017.03.025.", "ArticleIdList": ["10.1016/j.redox.2017.03.025", "PMC5385622", "28391184"]}, {"Citation": "Ide H., Lu Y., Noguchi T., Muto S., Okada H., Kawato S., Horie S. Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer. Cancer Sci. 2018;109:1230\u20131238. doi: 10.1111/cas.13517.", "ArticleIdList": ["10.1111/cas.13517", "PMC5891173", "29369461"]}, {"Citation": "Zhao W., Zhou X., Qi G., Guo Y. Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation. J. Biochem. Mol. Toxicol. 2018;32:1\u20135. doi: 10.1002/jbt.22049.", "ArticleIdList": ["10.1002/jbt.22049", "29485738"]}, {"Citation": "Katta S., Srivastava A., Thangapazham R.L., Rosner I.L., Cullen J., Li H., Sharad S. Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells. Int. J. Mol. Sci. 2019;20:4891. doi: 10.3390/ijms20194891.", "ArticleIdList": ["10.3390/ijms20194891", "PMC6801832", "31581661"]}, {"Citation": "Hong J.H., Ahn K.S., Bae E., Jeon S.S., Choi H.Y. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis. 2006;9:147\u2013152. doi: 10.1038/sj.pcan.4500856.", "ArticleIdList": ["10.1038/sj.pcan.4500856", "16389264"]}, {"Citation": "Santel T., Pflug G., Hemdan N.Y.A., Sch\u00e4fer A., Hollenbach M., Buchold M., Hintersdorf A., Lindner I., Otto A., Bigl M., et al. Curcumin inhibits glyoxalase 1: A possible link to its anti-inflammatory and anti-tumor activity. PLoS ONE. 2008;3:1\u201313. doi: 10.1371/journal.pone.0003508.", "ArticleIdList": ["10.1371/journal.pone.0003508", "PMC2567432", "18946510"]}, {"Citation": "Herman J.G., Stadelman H.L., Roselli C.E. Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. Int. J. Oncol. 2009;34:1319\u20131327.", "ArticleIdList": ["PMC2683974", "19360344"]}, {"Citation": "Liu S., Wang Z., Hu Z., Zeng X., Li Y., Su Y., Zhang C., Ye Z. Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-\u03baB and AP-1 pathway in vitro. J. Huazhong Univ. Sci. Technol. Med. Sci. 2011;31:530. doi: 10.1007/s11596-011-0485-1.", "ArticleIdList": ["10.1007/s11596-011-0485-1", "21823017"]}, {"Citation": "Killian P.H., Kronski E., Michalik K.M., Barbieri O., Astigiano S., Sommerhoff C.P., Pfeffer U., Nerlich A.G., Bachmeier B.E. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis. 2012;33:2507\u20132519. doi: 10.1093/carcin/bgs312.", "ArticleIdList": ["10.1093/carcin/bgs312", "23042094"]}, {"Citation": "Yu X.-L., Jing T., Zhao H., Li P.-J., Xu W.-H., Shang F.-F. Curcumin inhibits expression of inhibitor of DNA binding 1 in PC3 cells and xenografts. Asian Pac. J. Cancer Prev. 2014;15:1465\u20131470. doi: 10.7314/APJCP.2014.15.3.1465.", "ArticleIdList": ["10.7314/APJCP.2014.15.3.1465", "24606484"]}, {"Citation": "Li J., Xiang S., Zhang Q., Wu J., Tang Q., Zhou J., Yang L., Chen Z., Hann S.S. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-\u03baB/p65 and MUC1-C. J. Exp. Clin. Cancer Res. 2015;34:46. doi: 10.1186/s13046-015-0168-z.", "ArticleIdList": ["10.1186/s13046-015-0168-z", "PMC4446835", "25971429"]}, {"Citation": "Du Y., Long Q., Zhang L., Shi Y., Liu X., Li X., Guan B., Tian Y., Wang X., Li L., et al. Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1\u03b1 signaling. Int. J. Oncol. 2015;47:2064\u20132072. doi: 10.3892/ijo.2015.3202.", "ArticleIdList": ["10.3892/ijo.2015.3202", "PMC4665143", "26499200"]}, {"Citation": "Hu H.-J., Lin X.-L., Liu M.-H., Fan X.-J., Zou W.-W. Curcumin mediates reversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Met expression in DU145 cells. Oncol. Lett. 2016;11:1499\u20131505. doi: 10.3892/ol.2015.4063.", "ArticleIdList": ["10.3892/ol.2015.4063", "PMC4734299", "26893768"]}, {"Citation": "Sha J., Li J., Wang W., Pan L., Cheng J., Li L., Zhao H., Lin W. Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling. Biomed. Pharmacother. 2016;84:177\u2013184. doi: 10.1016/j.biopha.2016.09.037.", "ArticleIdList": ["10.1016/j.biopha.2016.09.037", "27657825"]}, {"Citation": "Yang C., Ma X., Wang Z., Zeng X., Hu Z., Ye Z., Shen G. Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation. Drug Des. Devel. Ther. 2017;11:431\u2013439. doi: 10.2147/DDDT.S126964.", "ArticleIdList": ["10.2147/DDDT.S126964", "PMC5317247", "28243065"]}, {"Citation": "Yang J., Wang C., Zhang Z., Chen X., Jia Y., Wang B., Kong T. Curcumin inhibits the survival and metastasis of prostate cancer cells via the Notch-1 signaling pathway. APMIS. 2017;125:134\u2013140. doi: 10.1111/apm.12650.", "ArticleIdList": ["10.1111/apm.12650", "28120490"]}, {"Citation": "Cao H., Yu H., Feng Y., Chen L., Liang F. Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis. Cancer Chemother. Pharmacol. 2017;79:985\u2013994. doi: 10.1007/s00280-017-3301-1.", "ArticleIdList": ["10.1007/s00280-017-3301-1", "28391351"]}, {"Citation": "Liu T., Chi H., Chen J., Chen C., Huang Y., Xi H., Xue J., Si Y. Curcumin suppresses proliferation and in vitro invasion of human prostate cancer stem cells by ceRNA effect of miR-145 and lncRNA-ROR. Gene. 2017;631:29\u201338. doi: 10.1016/j.gene.2017.08.008.", "ArticleIdList": ["10.1016/j.gene.2017.08.008", "28843521"]}, {"Citation": "Zhang H., Zheng J., Shen H., Huang Y., Liu T., Xi H., Chen C. Curcumin Suppresses In Vitro Proliferation and Invasion of Human Prostate Cancer Stem Cells by Modulating DLK1-DIO3 Imprinted Gene Cluster MicroRNAs. Genet. Test. Mol. Biomark. 2018;22:43\u201350. doi: 10.1089/gtmb.2017.0179.", "ArticleIdList": ["10.1089/gtmb.2017.0179", "29172709"]}, {"Citation": "Dorai T., Cao Y.C., Dorai B., Buttyan R., Katz A.E. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. 2001;47:293\u2013303. doi: 10.1002/pros.1074.", "ArticleIdList": ["10.1002/pros.1074", "11398177"]}, {"Citation": "Khor T.O., Keum Y.-S., Lin W., Kim J.-H., Hu R., Shen G., Xu C., Gopalakrishnan A., Reddy B., Zheng X., et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res. 2006;66:613\u2013621. doi: 10.1158/0008-5472.CAN-05-2708.", "ArticleIdList": ["10.1158/0008-5472.CAN-05-2708", "16423986"]}, {"Citation": "Shankar S., Ganapathy S., Chen Q., Srivastava R.K. Curcumin sensitizes TRAIL-resistant xenografts: Molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol. Cancer. 2008;7:16. doi: 10.1186/1476-4598-7-16.", "ArticleIdList": ["10.1186/1476-4598-7-16", "PMC2249593", "18226269"]}, {"Citation": "Barve A., Khor T.O., Hao X., Keum Y.-S., Yang C.S., Reddy B., Kong A.-N.T. Murine prostate cancer inhibition by dietary phytochemicals\u2014curcumin and phenyethylisothiocyanate. Pharm. Res. 2008;25:2181\u20132189. doi: 10.1007/s11095-008-9574-7.", "ArticleIdList": ["10.1007/s11095-008-9574-7", "PMC3465714", "18437538"]}, {"Citation": "Narayanan N.K., Nargi D., Randolph C., Narayanan B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer. 2009;125:1\u20138. doi: 10.1002/ijc.24336.", "ArticleIdList": ["10.1002/ijc.24336", "19326431"]}, {"Citation": "Fern\u00e1ndez-Mart\u00ednez A.B., Bajo A.M., Valdehita A., Isabel Arenas M., S\u00e1nchez-Chapado M., Carmena M.J., Prieto J.C. Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398. Peptides. 2009;30:2357\u20132364. doi: 10.1016/j.peptides.2009.09.018.", "ArticleIdList": ["10.1016/j.peptides.2009.09.018", "19772879"]}, {"Citation": "Yallapu M.M., Khan S., Maher D.M., Ebeling M.C., Sundram V., Chauhan N., Ganju A., Balakrishna S., Gupta B.K., Zafar N., et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials. 2014;35:8635\u20138648. doi: 10.1016/j.biomaterials.2014.06.040.", "ArticleIdList": ["10.1016/j.biomaterials.2014.06.040", "PMC4220612", "25028336"]}, {"Citation": "Dorai T., Diouri J., O\u2019Shea O., Doty S.B. Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo. J. Cancer Ther. 2014;5:369\u2013386. doi: 10.4236/jct.2014.54044.", "ArticleIdList": ["10.4236/jct.2014.54044", "PMC4060744", "24949215"]}, {"Citation": "Yang J., Ning J., Peng L., He D. Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer. Int. J. Clin. Exp. Pathol. 2015;8:9272\u20139278.", "ArticleIdList": ["PMC4583908", "26464676"]}, {"Citation": "Hong J.H., Lee G., Choi H.Y. Effect of curcumin on the interaction between androgen receptor and Wnt/\u03b2-catenin in LNCaP xenografts. Korean J. Urol. 2015;56:656\u2013665. doi: 10.4111/kju.2015.56.9.656.", "ArticleIdList": ["10.4111/kju.2015.56.9.656", "PMC4565901", "26366279"]}, {"Citation": "Lodi A., Saha A., Lu X., Wang B., Sentandreu E., Collins M., Kolonin M.G., DiGiovanni J., Tiziani S. Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism. Npj. Precis. Oncol. 2017;1:1\u201312. doi: 10.1038/s41698-017-0024-z.", "ArticleIdList": ["10.1038/s41698-017-0024-z", "PMC5705091", "29202102"]}, {"Citation": "Ma Q., Qian W., Tao W., Zhou Y., Xue B. Delivery of Curcumin Nanoliposomes Using Surface Modified With CD133 Aptamers For Prostate Cancer. Drug Des. Devel. Ther. 2019;13:4021\u20134033. doi: 10.2147/DDDT.S210949.", "ArticleIdList": ["10.2147/DDDT.S210949", "PMC6886545", "31819373"]}, {"Citation": "Li H., Zhang N., Hao Y., Wang Y., Jia S., Zhang H. Enhancement of curcumin antitumor efficacy and further photothermal ablation of tumor growth by single-walled carbon nanotubes delivery system in vivo. Drug Deliv. 2019;26:1017\u20131026. doi: 10.1080/10717544.2019.1672829.", "ArticleIdList": ["10.1080/10717544.2019.1672829", "PMC6781245", "31578087"]}, {"Citation": "Gracia E., Mancini A., Colapietro A., Mateo C., Gracia I., Festuccia C., Carmona M. Impregnation of Curcumin into a Biodegradable (Poly-lactic-co-glycolic acid, PLGA) Support, to Transfer Its Well Known In Vitro Effect to an In Vivo Prostate Cancer Model. Nutrients. 2019;11:2312. doi: 10.3390/nu11102312.", "ArticleIdList": ["10.3390/nu11102312", "PMC6835253", "31569529"]}, {"Citation": "De Velasco M.A., Lu Y., Kura Y., China T., Inoue Y., Nakayama A., Okada H., Horie S., Uemura H., Ide H. Chemopreventive effects of nanoparticle curcumin in a mouse model of Pten-deficient prostate cancer. Hum. Cell. 2020;33:730\u2013736. doi: 10.1007/s13577-020-00337-7.", "ArticleIdList": ["10.1007/s13577-020-00337-7", "32146706"]}]}], "History": [{"Year": "2020", "Month": "10", "Day": "7"}, {"Year": "2020", "Month": "10", "Day": "30"}, {"Year": "2020", "Month": "11", "Day": "4"}, {"Year": "2020", "Month": "11", "Day": "13", "Hour": "1", "Minute": "4"}, {"Year": "2020", "Month": "11", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "11", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["33182828", "PMC7696488", "10.3390/biom10111536", "biom10111536"]}}]}